DB22669ApprovedVaccines
Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen is a component of a recombinant influenza vaccine comprising a recombinant influenza hemagglutinin antigen. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses.
- First approval
- United States, 2025
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of August 01, 2025
Which companies are running trials of Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account